Aminoisoquinoline derivative and application thereof in preparation of antiviral drugs

By using aminoisoquinoline derivatives to target Scd1, inhibiting the replication and expression of viruses in cells, the problem of poor inhibition of antiviral drugs in the prior art has been solved, and the multiple RNAs and Effective inhibition of DNA viruses is broad-spectrum and low-toxic, and has good clinical application prospects.

CN118908892AActive Publication Date: 2024-11-08WUHAN UNIV

Patent Information

Application Number
CN202410966342.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

It is difficult to develop a broad-spectrum antiviral drug in the prior art, especially in the inhibition of multiple RNA and DNA viruses.

Method used

The aminoisoquinoline derivatives are used as the main component of antiviral drugs. By targeting the stearoyl Coenzyme A desaturase Scd1, the virus is inhibited in the nucleic acid replication and protein expression in the cell, thereby achieving effective inhibition of various viruses. .

Benefits of technology

Aminoisoquinoline derivatives significantly inhibit a variety of RNA and DNA viruses at low concentrations, have broad-spectrum and low toxicity, and do not affect the normal growth of host cells, and have good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908892A_ABST
    Figure CN118908892A_ABST
Patent Text Reader

Abstract

The invention provides an aminoisoquinoline derivative and application thereof in preparation of an antiviral drug. The aminoisoquinoline derivative is found to have a remarkable inhibition effect on various RNA viruses and DNA viruses, and the broad-spectrum property is good. The small-molecule inhibitor is low in toxicity and does not affect normal growth of host cells. And a relatively good antiviral effect can be achieved at a low concentration. Results of the invention show that the compound has potential to prepare anti-virus infection drugs and has good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the application of aminoisoquinoline derivatives in the preparation of antiviral drugs. Background Art

[0002] Stearoyl-CoA desaturase (Scd) is mainly involved in the synthesis of fatty acids in organisms, and its protein family members are very actively expressed in multiple species. It is worth noting that a delta-9 desaturase in the Scd family, namely Scd1, plays a vital role in the replication of various RNA viruses. The possible mechanism of action of Scd1 is to increase the membrane fluidity in the physiologically relevant phospholipid bilayer through the catalytic product oleic acid, or to change the curvature of the biological membrane structure. This characteristic of oleic acid molecules is conducive to the formation of closed vesicle-like structures in cells, and viruses need to use lipid droplets and specialized double-membrane vesicles in the host when replicating.

[0003] Isoquinoline derivatives are a very important class of nitrogen-containing heterocyclic compounds, which are widely found in natural products, drug molecules and organic functional materials. Studies have shown that these compounds have obvious physiological activities, such as anti-tumor, anti-analgesic, anti-arrhythmic and anti-thrombotic effects. Therefore, isoquinoline derivatives are widely used in the fields of medicine, agricultural chemistry and materials science. Especially in biomedicine, isoquinoline derivatives can reduce progesterone concentration, measure functional activity, and resist ulcers. With the deepening of research, isoquinoline derivatives also show good pharmacological activities, such as antiviral, anti-inflammatory and anti-insect activities.

[0004] At present, with the application of molecular targeted therapy in the treatment of malignant tumors, more and more virological studies have discovered new specific molecular sites. Targeted therapy targeting specific molecular sites can also greatly improve the host's antiviral effect.

[0005] Therefore, it is necessary to develop a new broad-spectrum antiviral drug. Summary of the invention

[0006] The purpose of the present invention is to provide the use of aminoisoquinoline derivatives in the preparation of antiviral drugs. The present application finds that aminoisoquinoline derivatives have significant inhibitory effects on a variety of RNA viruses and DNA viruses and have good broad-spectrum properties.

[0007] To achieve the above object, the present invention adopts the following technical solution:

[0008] In the first aspect of the present invention, there is provided an aminobenzoic acid derivative having the following structural formula:

[0009]

[0010] Wherein, R is H or an alkali metal atom.

[0011] In the second aspect of the present invention, a pharmaceutically acceptable salt of an aminoisoquinoline derivative is provided.

[0012] The preparation method of the aminobenzoic acid derivative comprises: reacting 7-amino-1,2,3,4-tetrahydroisoquinoline, naphthylic acid and cyclopropylacetic acid to prepare the aminobenzoic acid derivative. The aminobenzoic acid derivative is successfully prepared through detection.

[0013] Furthermore, the pharmaceutically acceptable salt includes inorganic salt or organic salt.

[0014] The inorganic salt includes one of hydrochloride, hydrobromide, sulfate, nitrate and phosphate; the organic salt includes one of methanesulfonate, maleate, tartrate, succinate, acetate, trifluoroacetate, fumarate, citrate, citrate, benzenesulfonate, benzoate, benzenesulfonate, lactate and malate.

[0015] In the third aspect of the present invention, there is provided the use of aminoisoquinoline derivatives in the preparation of antiviral drugs.

[0016] Furthermore, the virus includes RNA virus and DNA virus, the RNA virus includes one of foot-and-mouth disease virus, parainfluenza virus, rubella virus and coxsackie virus, and the DNA virus includes one of mumps virus and adenovirus.

[0017] Furthermore, the concentration of the aminoisoquinoline derivative is 0.01 μM-10 μM.

[0018] Furthermore, the aminoisoquinoline derivatives in the antiviral drug target the host stearoyl-CoA desaturase Scd1 for antiviral effects.

[0019] Furthermore, the antiviral drug also includes pharmaceutically acceptable excipients and carriers.

[0020] Furthermore, the auxiliary material includes at least one of a filler, a disintegrant, a binder, an excipient, a diluent, a lubricant, a sweetener or a colorant.

[0021] Furthermore, the dosage form of the antiviral drug includes at least one of granules, tablets, pills, capsules, injections or dispersions.

[0022] Furthermore, the antiviral mode of the antiviral drug includes: inhibiting viral nucleic acid replication, viral protein expression and infection in cells.

[0023] In a fourth aspect of the present invention, an antiviral drug is provided, wherein the active ingredient of the antiviral drug comprises the aminoisoquinoline derivative or the pharmaceutically acceptable salt.

[0024] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0025] The present invention provides an application of aminoisoquinoline derivatives in the preparation of antiviral drugs. The present application finds that aminoisoquinoline derivatives have significant inhibitory effects on a variety of RNA viruses and DNA viruses, and have good broad-spectrum properties. The small molecule inhibitor has low toxicity and does not affect the normal growth of host cells. It has a good antiviral effect at low concentrations. The results of the present invention show that the compound has the potential to prepare drugs for antiviral infection and has good clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following is a brief introduction to the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0027] Figure 1 It is the structural formula of aminobenzoic acid derivative;

[0028] Figure 2 It is the result of FMDV titer test;

[0029] Figure 3 HY-Q28157 inhibits FMDV replication;

[0030] Figure 4 The effect of HY-Q28157 treatment on the expression level of Scd1 in cells;

[0031] Figure 5 The effect of HY-Q28157 and oleic acid co-treatment on the expression level of FMDV 3D;

[0032] Figure 6 The effect of HY-Q28157 treatment on its antiviral effect; Figure 6 A is the dosing method, Figure 6 B: Different administration methods all have significant inhibitory effects on FMDV; Figure 6 C is a pattern diagram of adding HY-Q28157 8h or 4h before virus infection to explore its effect on virus infection; Figure 6 D is the qRT-PCR detection result.

[0033] Figure 7HY-Q28157 inhibits the replication of RNA viruses HPIV1, HPIV2, HPIV3, Rubella and MuV. DETAILED DESCRIPTION

[0034] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0035] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0036] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.

[0037] The technical solution of the embodiment of the present application is to solve the above technical problems, and the overall idea is as follows:

[0038] 1. Design and synthesize aminobenzoic acid derivatives with Scd1 as a specific target, the structural formula of which is as follows Figure 1 R is shown to be H or an alkali metal atom.

[0039] When R is H, it is named as aminobenzoic acid derivative HY-Q28157, and its chemical formula is C 24 H 22 N2O2, molecular weight is 370.44.

[0040] 2. Detect the toxicity of HY-Q28157 to host cells through CCK-8 experiment.

[0041] 3. Through qRT-PCR experiments, it was verified that the target of the inhibitor HY-Q28157 is Scd1.

[0042] 4. Through TCID 50 In this experiment, foot-and-mouth disease virus FMDV was used as a model, and the virus titer used was 5×10 - 6 TCID 50 / mL.

[0043] 5. The working concentration of the inhibitor HY-Q28157 was determined through qRT-PCR experiments, indicating that the small molecule compound HY-Q28157 can significantly inhibit foot-and-mouth disease virus (FMDV) at the RNA level at a concentration of 0.01 μM.

[0044] 6. Set up different inhibitor treatment methods to explore the best administration method of the inhibitor HY-Q28157. The results are as follows Figure 6 As shown in B, different administration methods all have significant inhibitory effects on FMDV, but the treatment method of administering the drug before infection is more effective.

[0045] 7. The broad-spectrum antiviral effect of the inhibitor HY-Q28157 was verified in parainfluenza virus, rubella virus, coxsackie virus, mumps virus and adenovirus.

[0046] In summary, the results of the present invention indicate that the compound has the potential to prepare a broad-spectrum antiviral drug and has good clinical application prospects.

[0047] The present application will be described in detail below with reference to embodiments and experimental data.

[0048] Example 1: Small molecule compound HY-Q28157 significantly inhibits foot-and-mouth disease virus (FMDV)

[0049] 1. Experimental reagents: Syrian hamster kidney cells BHK-21, rhesus monkey kidney cells LLC-MK2, African green monkey kidney cells Vero and human non-small cell lung cancer cells A549, CCK-8Kit.

[0050] 2. Experimental steps:

[0051] 1. BHK-21 cells were cultured at 5×10 4 The cells were inoculated at a density of 100 μL of cell suspension per well in a 96-well plate. When the cell confluence reached about 70-80%, the original culture medium in the well was aspirated and discarded, and fresh MEM culture medium with concentrations of 0.05 μM, 0.1 μM, 2 μM, 5 μM, and 10 μM of the small molecule compound HY-Q28157 was added. Eight replicates were set for each concentration, and DMSO was used as a blank control. After incubation in a 37°C incubator containing 5% CO2 for 48 hours, the original culture medium in the well was aspirated and discarded, and the medium was replaced with 100 μL of fresh culture medium containing 10% CCK-8 solution and incubated for 2 hours. The absorbance of each well was measured at 450 nm using a Labserv K3 microplate reader. The cell survival rate was calculated based on the absorbance of each well. The calculation method of the survival rate (%) is: OD 450 Sample / OD 450 Blank control × 100%.

[0052] Table 1. Toxicity of different concentrations of aminoisoquinoline derivatives HY-Q28157 to four cell types

[0053]

[0054]

[0055] 2. Use titer of 10 -4 TCID 50 / mL, 10 -5 TCID 50 / mL, 5×10 -6 TCID 50 / mL and 10 -6 TCID 50 / mL of FMDV was used to infect BHK-21 cells, and the time for cytopathic effect (CPE) to appear after cells were infected with viruses of different titers was observed.

[0056] The results are as follows Figure 2 As shown, the titer used in subsequent experiments was finally determined to be 5×10 -6 TCID 50 / mL of FMDV was used to detect the antiviral effect of HY-Q28157.

[0057] 3. When the density of BHK-21 cells in T-25 culture flasks reaches 80%-90%, digest the cells with trypsin and inoculate them into 24-well plates. Gently shake the 24-well plates to evenly distribute the cells and incubate them in a 37°C incubator containing 5% CO2. After the cells adhere to the wall, use a titer of 5×10 -6 TCID 50 / mL FMDV was infected, 100μL virus solution was added to each well, and the cells were placed in an incubator at 37℃ with 5% CO2 for incubation for 1h. The virus solution in the well plate was discarded, MEM medium containing 2% FBS was added, and compound HY-Q28157 was added to the final concentrations of 0.01μM, 0.1μM, 0.5μM, 1μM, 5μM, and 10μM, respectively. When CPE appeared in the cells, samples were collected, RNA was extracted, and qRT-PCR was performed.

[0058] The results are as follows Figure 3 As shown, it is shown that the small molecule compound HY-Q28157 can significantly inhibit foot-and-mouth disease virus (FMDV) at the RNA level at a concentration of 0.01 μM.

[0059] 4. In order to verify that the designed and synthesized small molecule compound HY-Q28157 regulates the replication of FMDV by inhibiting Scd1, BHK-21 cells were inoculated into 24-well plates, gently shaken to evenly distribute the cells, and incubated in a 37°C incubator containing 5% CO2. After the cells adhered to the wall, a titer of 5×10 -6Infect with FMDV, add 100 μL virus solution to each well, incubate at 37℃ with 5% CO2 for 1 hour, then change to 2% MEM medium and continue culturing. When CPE appears in the cells, collect samples and perform qRT-PCR detection. The results show that ( Figure 4 ), similar to the commercial Scd1 inhibitor MK-8245, HY-Q28157 did not affect the RNA level of Scd1. Oleic acid (OA) is the end product of Scd1 catalysis. HY-Q28157 or the commercial Scd1 inhibitor MK-8245 was used for treatment, and 200 μM oleic acid was added for continued culture. qRT-PCR detection showed that both HY-Q28157 and MK-8245 could inhibit the RNA level of FMDV 3D, but after the addition of oleic acid, the expression of 3D was significantly restored ( Figure 5 ).

[0060] Example 2: Effect of the addition method of the small molecule compound HY-Q28157 on its antiviral effect

[0061] In order to study the effect of the addition method of the small molecule compound HY-Q28157 on its antiviral effect, two methods were selected: adding HY-Q28157 8 hours before virus infection and adding the same concentration of HY-Q28157 when changing the medium after virus infection, or adding it only when changing the medium 1 hour after virus infection. The schematic diagram of the drug addition method is shown in the figure. Figure 6 A. After culturing the cells for 24 hours, samples were collected for qRT-PCR detection to explore the effects of different administration methods on the antiviral effect of HY-Q28157.

[0062] The results are as follows Figure 6 As shown in B, different administration methods have significant inhibitory effects on FMDV, but the administration method before infection is more effective. In addition, in order to determine the time of adding the compound before infection, HY-Q28157 was added 8h or 4h before virus infection to explore its effect on virus infection. The model diagram is shown in Figure 6 C, and the results of qRT-PCR showed that ( Figure 6 D) There was no significant difference in the effect of adding HY-Q28157 8h or 4h before infection on FMDV infection.

[0063] Example 3: The broad spectrum of small molecule compound HY-Q28157 in regulating viral replication by inhibiting Scd1

[0064] In order to verify the broad spectrum of the small molecule compound HY-Q28157 in regulating viral replication by inhibiting Scd1. The regulation of the small molecule compound HY-Q28157 on the level of viral nucleic acid was verified in RNA viruses: parainfluenza virus type 1 (HPIV1), type 2 (HPIV2), type 3 (HPIV3), rubella virus (Rubella), mumps virus (MuV) and DNA viruses: adenovirus type 3 (ADV3), adenovirus type 5 (ADV5). The host cells LLC-MK2 and A549 cells corresponding to the above viruses were inoculated into 24-well plates, and the cells were gently shaken after plating to make the cells evenly distributed, and incubated in an incubator at 37°C containing 5% CO2. After the cells adhered to the wall, the corresponding host cells were infected with the appropriate titer of virus, 100 μL of virus solution was added to each well, and incubated in an incubator at 37°C containing 5% CO2 for 1h. The virus solution in the well plate was discarded, MEM medium containing 2% FBS was added, and compound HY-Q28157 was added to a final concentration of 0.1 μM and 5 μM, respectively. When the cells showed CPE, samples were collected, RNA was extracted, and qRT-PCR was performed. The results are shown in Table 2 and Figure 7 shown.

[0065] Table 2 HY-Q28157 inhibits the replication of DNA viruses ADV3 and ADV5

[0066]

[0067] From Table 2, Figure 7 It can be seen that the small molecule compound HY-Q28157 has different degrees of inhibition on the nucleic acid levels of HPIV1, HPIV2, HPIV3, Rubella, MuV, ADV3, and ADV5, indicating that HY-Q28157 has a certain broad spectrum of inhibition of viral replication. It has the potential to further develop and prepare a clinically effective broad-spectrum antiviral infection drug.

[0068] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0069] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0070] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. An aminobenzoic acid derivative, characterized in that: The aminobenzoic acid derivative has the following structural formula: Wherein, R is H or an alkali metal atom.

2. A pharmaceutically acceptable salt of the aminoisoquinoline derivative according to claim 1.

3. The pharmaceutically acceptable salt according to claim 2, characterized in that The pharmaceutically acceptable salts include inorganic salts or organic salts.

4. Use of the aminoisoquinoline derivative according to claim 1 or the pharmaceutically acceptable salt according to any one of claims 2 to 3 in the preparation of antiviral drugs.

5. The use according to claim 4, characterized in that: The viruses include RNA viruses and DNA viruses. The RNA viruses include one of foot-and-mouth disease virus, parainfluenza virus, rubella virus and coxsackie virus. The DNA viruses include one of mumps virus and adenovirus.

6. The use according to claim 5, characterized in that: The concentration of the aminoisoquinoline derivative HY-Q28157 is 0.01 μM-10 μM.

7. An antiviral drug, characterized in that: The active ingredient of the antiviral drug comprises the aminoisoquinoline derivative according to claim 1 or the pharmaceutically acceptable salt according to any one of claims 2-3.

8. The antiviral drug according to claim 7, characterized in that: The antiviral drug also includes pharmaceutically acceptable adjuvants and carriers.

9. The antiviral drug according to claim 8, characterized in that The auxiliary materials include at least one of a filler, a disintegrant, a binder, an excipient, a diluent, a lubricant, a sweetener or a colorant.

10. The antiviral drug according to claim 7, characterized in that: The dosage form of the antiviral drug includes at least one of granules, tablets, pills, capsules, injections or dispersions.

Citation Information

Patent Citations

  • Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same

    CN108779104A

  • Substituted isoquinoline derivatives and their use as anticonvulsants

    CN1284946A

  • Amide derivatives

    CN1473157A

  • Bicycloheteroaryl compounds as P2X7 modulators and uses thereof

    US20060217448A1

  • Isoindoline derivatives

    US20180327355A1

Cited By

  • Application of aminoimidazole compound HY-W051988 and derivative thereof in resisting RNA (Ribonucleic Acid) virus

    CN120093737A